Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
Identifieur interne : 000A33 ( Main/Curation ); précédent : 000A32; suivant : 000A34Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
Auteurs : Jean-Marc Taymans [États-Unis, Belgique] ; Mark R. Cookson [États-Unis]Source :
- BioEssays [ 0265-9247 ] ; 2010-03.
English descriptors
- KwdEn :
Abstract
Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.
Url:
DOI: 10.1002/bies.200900163
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B79
Links to Exploration step
ISTEX:BAD8011D8F2673D5ABA6187FCDF1135776A1DE8ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><author><name sortKey="Taymans, Jean Arc" sort="Taymans, Jean Arc" uniqKey="Taymans J" first="Jean-Marc" last="Taymans">Jean-Marc Taymans</name><affiliation wicri:level="1"><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Cookson, Mark R" sort="Cookson, Mark R" uniqKey="Cookson M" first="Mark R." last="Cookson">Mark R. Cookson</name><affiliation wicri:level="1"><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/bies.200900163</idno><idno type="url">https://api.istex.fr/document/BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000B79</idno><idno type="wicri:Area/Main/Curation">000A33</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau</title><author><name sortKey="Taymans, Jean Arc" sort="Taymans, Jean Arc" uniqKey="Taymans J" first="Jean-Marc" last="Taymans">Jean-Marc Taymans</name><affiliation wicri:level="1"><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation><affiliation wicri:level="1"><mods:affiliation>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven, Belgium</mods:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Laboratory for Neurobiology and Gene Therapy, Division of Molecular Medicine, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven, Leuven</wicri:regionArea></affiliation></author><author><name sortKey="Cookson, Mark R" sort="Cookson, Mark R" uniqKey="Cookson M" first="Mark R." last="Cookson">Mark R. Cookson</name><affiliation wicri:level="1"><mods:affiliation>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD, USA</mods:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Cell Biology and Gene Expression Unit, Laboratory of Neurogenetics, NIA, National Institutes of Health, Bethesda, MD</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">BioEssays</title><title level="j" type="abbrev">Bioessays</title><idno type="ISSN">0265-9247</idno><idno type="eISSN">1521-1878</idno><imprint><publisher>WILEY‐VCH Verlag</publisher><pubPlace>Weinheim</pubPlace><date type="published" when="2010-03">2010-03</date><biblScope unit="volume">32</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="227">227</biblScope><biblScope unit="page" to="235">235</biblScope></imprint><idno type="ISSN">0265-9247</idno></series><idno type="istex">BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E</idno><idno type="DOI">10.1002/bies.200900163</idno><idno type="ArticleID">BIES200900163</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0265-9247</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>genetics</term><term>kinases</term><term>microtubule</term><term>neurodegeneration</term><term>synapse</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is generally sporadic but a number of genetic diseases have parkinsonism as a clinical feature. Two dominant genes, α‐synuclein (SNCA) and leucine‐rich repeat kinase 2 (LRRK2), are important for understanding inherited and sporadic PD. SNCA is a major component of pathologic inclusions termed Lewy bodies found in PD. LRRK2 is found in a significant proportion of PD cases. These two proteins may be linked as most LRRK2 PD cases have SNCA‐positive Lewy bodies. Mutations in both proteins are associated with toxic effects in model systems although mechanisms are unclear. LRRK2 is an intracellular signaling protein possessing both GTPase and kinase activities that may contribute to pathogenicity. A third protein, tau, is implicated as a risk factor for PD. We discuss the potential relationship between these genes and suggest a model for PD pathogenesis where LRRK2 is upstream of pathogenic effects through SNCA, tau, or both proteins.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A33 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000A33 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Curation
|type= RBID
|clé= ISTEX:BAD8011D8F2673D5ABA6187FCDF1135776A1DE8E
|texte= Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, α‐synuclein, and tau
}}
| This area was generated with Dilib version V0.6.23. |  |